Skip to main content
SpringerLink
Log in

The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms

  • Chapter
  • First Online:
Principles of Diabetes Mellitus

Abstract

Theories on a connection between diabetes, obesity, and cancer have existed for over a century. In 1910, despite their elusive etiologies, Maynard hypothesized that a correlation between diabetes and cancer could exist, as both conditions were increasing in prevalence and had similar age distributions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Maynard GD. A statistical study in cancer death-rates. Biometrika. 1910;7:276–304.

    Article  Google Scholar 

  2. Kessler II. Cancer and diabetes mellitus a review of the literature. J Chronic Dis. 1971;23:579–600.

    Article  PubMed  CAS  Google Scholar 

  3. Sell C. Caloric restriction and insulin-like growth factors in aging and cancer. Horm Metab Res. 2003;35:705–711.

    Article  PubMed  CAS  Google Scholar 

  4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.

    Article  PubMed  Google Scholar 

  5. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–1167.

    Article  PubMed  Google Scholar 

  6. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–1877.

    Article  PubMed  Google Scholar 

  7. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202.

    Article  PubMed  CAS  Google Scholar 

  8. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30:561–567.

    Article  PubMed  Google Scholar 

  9. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003;157:1092–1100.

    Article  PubMed  Google Scholar 

  10. Zendehdel K, Nyren O, Ostenson C-G, Adami H-O, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003;95:1797–1800.

    PubMed  Google Scholar 

  11. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365–1374.

    Article  PubMed  CAS  Google Scholar 

  12. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6:103–111.

    Article  PubMed  CAS  Google Scholar 

  13. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes – a follow-up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241:471–475.

    Article  PubMed  CAS  Google Scholar 

  14. Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005;93:1062–1067.

    Article  PubMed  CAS  Google Scholar 

  15. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003;26:1047–1051.

    Article  PubMed  Google Scholar 

  16. Kath R, Schiel R, Müller UA, Höffken K. Malignancies in patients with insulin-treated diabetes mellitus. J Cancer Res Clin Oncol. 2000;126:412–417.

    Article  PubMed  CAS  Google Scholar 

  17. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056–2062.

    Article  PubMed  Google Scholar 

  18. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856–862.

    Article  PubMed  CAS  Google Scholar 

  19. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49:2819–2823.

    Article  PubMed  CAS  Google Scholar 

  20. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071–1078.

    Article  PubMed  CAS  Google Scholar 

  21. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–2083.

    Article  PubMed  CAS  Google Scholar 

  22. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–1687.

    Article  PubMed  Google Scholar 

  23. Zimmet PZ, Alberti KGMM. Introduction: globalization and the non-communicable disease epidemic. Obesity. 2006;14:1–3.

    Article  PubMed  Google Scholar 

  24. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the united states, 1999–2004. JAMA. 2006;295:1549–1555.

    Article  PubMed  CAS  Google Scholar 

  25. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the multicultural community health assessment trial (M-CHAT). Am J Clinl Nutr. 2007;86:353–359.

    CAS  Google Scholar 

  26. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–878.

    Article  PubMed  Google Scholar 

  27. Pan SY, Johnson KC, Ugnat A-M, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159:259–268.

    Article  PubMed  Google Scholar 

  28. Polednak AP. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev. 2003;27:415–421.

    Article  PubMed  Google Scholar 

  29. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  30. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91:421–430.

    Article  PubMed  CAS  Google Scholar 

  31. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591.

    Article  PubMed  CAS  Google Scholar 

  32. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care. 2003;26:1752–1758.

    Article  PubMed  Google Scholar 

  33. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13:325–332.

    Article  PubMed  Google Scholar 

  34. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276–280.

    Article  PubMed  Google Scholar 

  35. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst. 2003;95:1244–1248.

    Article  PubMed  Google Scholar 

  36. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:822–828.

    PubMed  Google Scholar 

  37. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women’s Health Study. Cancer. 2004;100:1515–1521.

    Article  PubMed  Google Scholar 

  38. Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006;107:1520–1524.

    Article  PubMed  Google Scholar 

  39. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Euro J Cancer. 2007;43:690–709.

    Article  Google Scholar 

  40. Adler AI, Weiss NS, Kamb ML, Lyon JL. Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States). Cancer Causes Control. 1996;7:475–478.

    Article  PubMed  CAS  Google Scholar 

  41. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami H-O. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control. 2002;13:759–764.

    Article  PubMed  Google Scholar 

  42. Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer. 2005;92:2070–2075.

    Article  PubMed  CAS  Google Scholar 

  43. Lacey J, Frisch M, Brinton L, et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control. 2001;12:153–161.

    Article  PubMed  Google Scholar 

  44. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – A 24-year population-based study. Gynecol Oncol. 2000;78:97–105.

    Article  PubMed  CAS  Google Scholar 

  45. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15:1977–1983.

    Article  PubMed  Google Scholar 

  46. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88–97.

    Article  PubMed  Google Scholar 

  47. Palma D, Pickles T, Tyldesley S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int. 2007;100:315–319.

    Article  PubMed  Google Scholar 

  48. Calton B, Chang S, Wright M, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2007;18:493–503.

    Article  PubMed  Google Scholar 

  49. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109:875–881.

    Article  PubMed  Google Scholar 

  50. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer. 2004;90:2171–2175.

    PubMed  CAS  Google Scholar 

  51. Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia. 1999;42:107–112.

    Article  PubMed  CAS  Google Scholar 

  52. Chow W-H, Gridley G, Fraumeni JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in Men. N Engl J Med. 2000;343:1305–1311.

    Article  PubMed  CAS  Google Scholar 

  53. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–1365.

    Article  PubMed  CAS  Google Scholar 

  54. Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the Physicians’ Health Study. Cancer Epidemiol Biomarkers Prev. 2006;15:2391–2397.

    Article  PubMed  Google Scholar 

  55. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542–547.

    Article  PubMed  CAS  Google Scholar 

  56. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clinl Nutr. 2007;86:556–565.

    CAS  Google Scholar 

  57. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004.

    Article  PubMed  CAS  Google Scholar 

  58. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1–9.

    PubMed  CAS  Google Scholar 

  59. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132:3456S–64S.

    PubMed  CAS  Google Scholar 

  60. Bingham SA, Norat T, Moskal A, et al. Is the association with fiber from foods in colorectal cancer confounded by folate intake? Cancer Epidemiol Biomarkers Prev. 2005;14:1552–1556.

    Article  PubMed  CAS  Google Scholar 

  61. Norat T, Bingham S, Ferrari P, et al. Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97:906–916.

    Article  PubMed  Google Scholar 

  62. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298:754–764.

    Article  PubMed  CAS  Google Scholar 

  63. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.

    Article  PubMed  CAS  Google Scholar 

  64. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002;132:3467S–3470.

    PubMed  CAS  Google Scholar 

  65. Ji BT, Chow WH, Yang G, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 1997;6:481–485.

    PubMed  CAS  Google Scholar 

  66. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211.

    PubMed  Google Scholar 

  67. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006;118:2105–2109.

    Article  PubMed  CAS  Google Scholar 

  68. Rubenstein JH, Davis J, Marrero JA, Inadomi JM. Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther. 2005;22:267–271.

    Article  PubMed  CAS  Google Scholar 

  69. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003;2:4.

    Article  PubMed  Google Scholar 

  70. Noy A, Bilezikian JP. Clinical review 63: diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab. 1994;79:1223–1231.

    Article  PubMed  CAS  Google Scholar 

  71. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283:2552–2558.

    Article  PubMed  CAS  Google Scholar 

  72. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605–1609.

    Article  PubMed  CAS  Google Scholar 

  73. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9:403–410.

    Article  PubMed  CAS  Google Scholar 

  74. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504–511.

    PubMed  Google Scholar 

  75. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:459–466.

    Article  PubMed  Google Scholar 

  76. Canoy D, Wareham N, Luben R, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obesity Res. 2005;13:1466–1475.

    Article  Google Scholar 

  77. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 2000;11:915–923.

    Article  PubMed  CAS  Google Scholar 

  78. Adami HO, Chow WH, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–1477.

    Article  PubMed  CAS  Google Scholar 

  79. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295–1302.

    Article  PubMed  Google Scholar 

  80. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221–1228.

    Article  PubMed  Google Scholar 

  81. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620–626.

    Article  PubMed  Google Scholar 

  82. Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol. 2007;19:623–630.

    Article  PubMed  Google Scholar 

  83. Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer. 2007;121:2512–2516.

    Article  PubMed  CAS  Google Scholar 

  84. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin’s lymphoma: a meta-analysis. Int J Cancer. 2007;121:1564–1570.

    Article  PubMed  CAS  Google Scholar 

  85. Lim U, Morton LM, Subar AF, et al. Alcohol, smoking, and body size in relation to incident Hodgkin’s and non-Hodgkin’s lymphoma risk. Am J Epidemiol. 2007;166:697–708.

    Article  PubMed  Google Scholar 

  86. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2007;16:1474–1478.

    Article  PubMed  Google Scholar 

  87. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25:2063–2069.

    Article  PubMed  Google Scholar 

  88. Chiu BCH, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2348–2354.

    Article  PubMed  CAS  Google Scholar 

  89. Olson JE, Yang P, Schmitz K, Vierkant RA, Cerhan JR, Sellers TA. Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol. 2002;156:606–615.

    Article  PubMed  CAS  Google Scholar 

  90. Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28:590–594.

    Article  PubMed  Google Scholar 

  91. Kanashiki M, Sairenchi T, Saito Y, Ishikawa H, Satoh H, Sekizawa K. Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program. Chest. 2005;128:1490–1496.

    Article  PubMed  Google Scholar 

  92. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16:83–89.

    Article  PubMed  Google Scholar 

  93. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17:328–336.

    Article  PubMed  CAS  Google Scholar 

  94. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314–322.

    Article  PubMed  CAS  Google Scholar 

  95. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–137.

    Article  PubMed  CAS  Google Scholar 

  96. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278:E967–E976.

    PubMed  CAS  Google Scholar 

  97. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–854.

    Article  PubMed  CAS  Google Scholar 

  98. Chen JC, Shao ZM, Sheikh MS, et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol. 1994;158:69–78.

    Article  PubMed  CAS  Google Scholar 

  99. Morris JK, George LM, Wu T, Wald NJ. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer. 2006;95:112–117.

    Article  PubMed  CAS  Google Scholar 

  100. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–1353.

    Article  PubMed  CAS  Google Scholar 

  101. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 2005;103:76–84.

    Article  PubMed  CAS  Google Scholar 

  102. Janssen JAMJL, Wildhagen MF, Ito K, et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab. 2004;89:4391–4396.

    Article  PubMed  CAS  Google Scholar 

  103. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92:1592–1600.

    Article  PubMed  CAS  Google Scholar 

  104. Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;121:368–376.

    Article  PubMed  CAS  Google Scholar 

  105. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:763–768.

    Article  PubMed  CAS  Google Scholar 

  106. Severi G, Morris HA, MacInnis RJ, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1137–1141.

    Article  PubMed  CAS  Google Scholar 

  107. Allen NE, Key TJ, Appleby PN, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2007;16:1121–1127.

    Article  PubMed  CAS  Google Scholar 

  108. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1566–1573.

    PubMed  CAS  Google Scholar 

  109. Tran TT, Gupta N, Goh T, et al. Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev. 2003;12:47–56.

    PubMed  CAS  Google Scholar 

  110. Koohestani N, Chia MC, Pham NA, et al. Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy. Carcinogenesis. 1998;19:1679–1684.

    Article  PubMed  CAS  Google Scholar 

  111. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–258.

    Google Scholar 

  112. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52(9):1699–1708.

    Google Scholar 

  113. Novosyadlyy R, Vijayakumar A, Lann D, Fierz Y, Kurshnan N, LeRoith D. Physical and functional interaction between polyoma virus T antigen and insulin and IGF-I receptors is required for oncogene activation and tumor initiation. Oncogene. 2009;doi:10.1038/onc.2009.209.

    Google Scholar 

  114. Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene. 1997;14:1725–1734.

    Article  PubMed  CAS  Google Scholar 

  115. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 2001;85:428–430.

    Article  PubMed  CAS  Google Scholar 

  116. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997;57:4667–4672.

    PubMed  CAS  Google Scholar 

  117. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80–101.

    PubMed  CAS  Google Scholar 

  118. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62:1030–1035.

    PubMed  CAS  Google Scholar 

  119. Yang X-F, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996;56:1509–1511.

    PubMed  CAS  Google Scholar 

  120. Deitel K, Dantzer D, Ferguson P, et al. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. J Surg Oncol. 2002;81:75–79.

    Article  PubMed  CAS  Google Scholar 

  121. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor i levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003;63:4384–4388.

    PubMed  CAS  Google Scholar 

  122. Ramsey MM, Ingram RL, Cashion AB, et al. Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis. Endocrinology. 2002;143:4139–4142.

    Article  PubMed  CAS  Google Scholar 

  123. Swanson SM, Unterman TG. The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis. 2002;23:977–982.

    Article  PubMed  CAS  Google Scholar 

  124. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997;57:2687–2693.

    PubMed  CAS  Google Scholar 

  125. Yakar S, Pennisi P, Kim CH, et al. Studies involving the GH-IGF axis: lessons from IGF-I and IGF-I receptor gene targeting mouse models. J Endocrinol Invest. 2005;28:19–22.

    PubMed  CAS  Google Scholar 

  126. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16:143–163.

    PubMed  CAS  Google Scholar 

  127. Le Roith D, Bondy C, Yakar S, Liu J-L, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53–74.

    Article  PubMed  Google Scholar 

  128. Yakar S, LeRoith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev. 2005;16:407–420.

    Article  PubMed  CAS  Google Scholar 

  129. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006;20:267–275.

    Article  PubMed  CAS  Google Scholar 

  130. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006;17:305–323.

    Article  PubMed  CAS  Google Scholar 

  131. White MF. The IRS-signalling system: A network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182:3–11.

    Article  PubMed  CAS  Google Scholar 

  132. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1–24.

    Article  PubMed  CAS  Google Scholar 

  133. Owerbach D, Bell GI, Rutter WJ, Shows TB. The insulin gene is located on chromosome 11 in humans. Nature. 1980;286:82–84.

    Article  PubMed  CAS  Google Scholar 

  134. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet. 1995;9:293–298.

    Article  PubMed  CAS  Google Scholar 

  135. Lucassen AM, Julier C, Beressi J-P, et al. Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet. 1993;4:305–310.

    Article  PubMed  CAS  Google Scholar 

  136. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet. 1996;30:343–370.

    Article  PubMed  CAS  Google Scholar 

  137. Rodriguez S, Gaunt T, Day I. Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum Genet. 2007;122:1–21.

    Article  PubMed  CAS  Google Scholar 

  138. Ho GY, Melman A, Liu SM, et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer. 2003;88:263–269.

    Article  PubMed  CAS  Google Scholar 

  139. Claeys GB, Sarma AV, Dunn RL, et al. INSPstI polymorphism and prostate cancer in African-American men. Prostate. 2005;65:83–87.

    Article  PubMed  CAS  Google Scholar 

  140. Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. The Prostate. 2005;64:168–174.

    Article  PubMed  CAS  Google Scholar 

  141. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1204–1211.

    Article  PubMed  CAS  Google Scholar 

  142. Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev. 2006;15:2461–2466.

    Article  PubMed  CAS  Google Scholar 

  143. Tsuchiya N, Wang L, Suzuki H, et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol. 2006;24:1982–1989.

    Article  PubMed  CAS  Google Scholar 

  144. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst. 2006;98:123–134.

    Article  PubMed  CAS  Google Scholar 

  145. Wagner K, Hemminki K, Försti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treatment. 2007;104:233–248.

    Article  CAS  Google Scholar 

  146. Johansson M, McKay JD, Stattin P, et al. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer. 2007;120:539–542.

    Article  PubMed  CAS  Google Scholar 

  147. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 2006;15:1–10.

    Article  PubMed  CAS  Google Scholar 

  148. Murrell A, Heeson S, Cooper WN, et al. An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype. Hum Mol Genet. 2004;13:247–255.

    Article  PubMed  CAS  Google Scholar 

  149. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753–1755.

    Article  PubMed  CAS  Google Scholar 

  150. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:1657–1659.

    Article  PubMed  CAS  Google Scholar 

  151. Marini MA, Frontoni S, Mineo D, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:3368–3371.

    Article  PubMed  CAS  Google Scholar 

  152. Perticone F, Sciacqua A, Scozzafava A, et al. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab. 2004;89:3606–3609.

    Article  PubMed  CAS  Google Scholar 

  153. Hribal ML, Federici M, Porzio O, et al. The Gly->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab. 2000;85:2004–2013.

    Article  PubMed  CAS  Google Scholar 

  154. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer. 2006;94:299–307.

    Article  PubMed  CAS  Google Scholar 

  155. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86:1274–1280.

    Article  PubMed  CAS  Google Scholar 

  156. Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006;16:693–701.

    Article  PubMed  CAS  Google Scholar 

  157. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene. 2006;25:6373–6383.

    Article  PubMed  CAS  Google Scholar 

  158. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–526.

    Article  PubMed  CAS  Google Scholar 

  159. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80–83.

    Article  PubMed  CAS  Google Scholar 

  160. Shieh S-Y, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325–334.

    Article  PubMed  CAS  Google Scholar 

  161. Sugimoto Y, Whitman M, Cantley LC, Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA. 1984;81:2117–2121.

    Article  PubMed  CAS  Google Scholar 

  162. Ogg S, Paradis S, Gottlieb S, et al. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature. 1997;389:994–999.

    Article  PubMed  CAS  Google Scholar 

  163. Greer EL, Dowlatshahi D, Banko MR, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol. 2007;17:1646–1656.

    Article  PubMed  CAS  Google Scholar 

  164. Shen W-H, Zhou J-H, Broussard SR, Freund GG, Dantzer R, Kelley KW. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res. 2002;62:4746–4756.

    PubMed  CAS  Google Scholar 

  165. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem. 2002;277:15600–15606.

    Article  PubMed  CAS  Google Scholar 

  166. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao G-H, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001;61:589–593.

    PubMed  CAS  Google Scholar 

  167. Qi H, Xiao L, Lingyun W, et al. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis. Ann Hematol. 2006;85:95–101.

    Article  PubMed  CAS  Google Scholar 

  168. Giardiello FM, Brensinger JD, TersmetteS AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–1453.

    Article  PubMed  CAS  Google Scholar 

  169. Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell. 2001;7:1307–1319.

    Article  PubMed  CAS  Google Scholar 

  170. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999;154:1835–1840.

    Article  PubMed  CAS  Google Scholar 

  171. Rowan A, Bataille V, MacKie R, et al. Somatic mutations in the Peutz-Jegners (LKB1//STKII) gene in sporadic malignant melanomas. J Invest Dermatol. 1999;112:509–511.

    Article  PubMed  CAS  Google Scholar 

  172. Guervos MA, Marcos CA, Hermsen M, Nuno AS, Suarez C, Llorente JL. Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas. Cell Oncol. 2007;29:327–334.

    PubMed  CAS  Google Scholar 

  173. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–1646.

    Article  PubMed  CAS  Google Scholar 

  174. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305.

    Article  PubMed  Google Scholar 

  175. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258.

    Article  PubMed  Google Scholar 

  176. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–10273.

    Article  PubMed  CAS  Google Scholar 

  177. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205–38211.

    Article  PubMed  CAS  Google Scholar 

  178. Canonici A, Steelant W, Rigot V, et al. Insulin-like growth factor-I receptor, E-cadherin and alphav integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer. 2008;1:572-582.

    Article  CAS  Google Scholar 

  179. Becker K-F, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845–3852.

    PubMed  CAS  Google Scholar 

  180. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432.

    Article  PubMed  CAS  Google Scholar 

  181. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–884.

    Article  PubMed  CAS  Google Scholar 

  182. Maffei M, Fei H, Lee GH, et al. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci USA. 1995;92:6957–6960.

    Article  PubMed  CAS  Google Scholar 

  183. Fung TT, Rimm EB, Spiegelman D, et al. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clinl Nutr. 2001;73:61–67.

    CAS  Google Scholar 

  184. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972–980.

    PubMed  CAS  Google Scholar 

  185. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005;330:280–289.

    Article  PubMed  Google Scholar 

  186. Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999;93:1668–1676.

    PubMed  CAS  Google Scholar 

  187. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003;278:42660–42667.

    Article  PubMed  CAS  Google Scholar 

  188. Somasundar P, Riggs D, Jackson B, Vona-Davis L, McFadden DW. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg. 2003;186:575–578.

    Article  PubMed  CAS  Google Scholar 

  189. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin – a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst. 2002;94:1704–1711.

    PubMed  CAS  Google Scholar 

  190. Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-[alpha] and PPAR expression. Biochim Biophys Acta. 2002;1592:107–116.

    PubMed  CAS  Google Scholar 

  191. Hardwick JCH, Van Den Brink GR, Offerhaus GJ, Van Deventer SJH, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79–90.

    Article  PubMed  CAS  Google Scholar 

  192. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–165.

    Article  PubMed  CAS  Google Scholar 

  193. Kim C-H, Pennisi P, Zhao H, et al. MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab. 2006;291:E298–E305.

    Article  PubMed  CAS  Google Scholar 

  194. Tsatsanis C, Zacharioudaki V, Androulidaki A, et al. Peripheral factors in the metabolic syndrome: the pivotal role of adiponectin. Ann N Y Acad Sci. 2006;1083:185–195.

    Article  PubMed  CAS  Google Scholar 

  195. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 2002;8:1288–1295.

    Article  PubMed  CAS  Google Scholar 

  196. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–1225.

    Article  PubMed  CAS  Google Scholar 

  197. Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006;2006:re7.

    Article  PubMed  Google Scholar 

  198. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98:1120–1127.

    Article  PubMed  CAS  Google Scholar 

  199. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U.S.A. 2004;101:2476–2481.

    Article  PubMed  CAS  Google Scholar 

  200. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res. 2007;67:2391–2393.

    Article  PubMed  CAS  Google Scholar 

  201. Berndt J, Kovacs P, Ruschke K, et al. Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. Diabetologia. 2007;50:1472–1480.

    Article  PubMed  CAS  Google Scholar 

  202. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007;38:842–849.

    Article  PubMed  CAS  Google Scholar 

  203. Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT. Spot 14: a marker of aggressive breast cancer and a potential therapeutic target. Endocrinology. 2006;147:4048–4055.

    Article  PubMed  CAS  Google Scholar 

  204. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U.S.A. 2004;101:10715–10720.

    Article  PubMed  CAS  Google Scholar 

  205. Hardy S, St-Onge GG, Joly E, Langelier Y, Prentki M. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J Biol Chem. 2005;280:13285–13291.

    Article  PubMed  CAS  Google Scholar 

  206. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070–2075.

    Article  PubMed  CAS  Google Scholar 

  207. Gonullu G, Ersoy C, Ersoy A, et al. Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer. Cytokine. 2005;31:264–269.

    Article  PubMed  CAS  Google Scholar 

  208. Cozen W, Gebregziabher M, Conti DV, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev. 2006;15:2285–2291.

    Article  PubMed  CAS  Google Scholar 

  209. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726–731.

    Article  PubMed  CAS  Google Scholar 

  210. Plaisance I, Morandi C, Murigande C, Brink M. TNF-{alpha} increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3-kinase and MEK. Am J Physiol Endocrinol Metab. 2008;294:E241–E250, 00129.2007.

    Article  PubMed  CAS  Google Scholar 

  211. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-{alpha} concentrations in a native canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84:272–278.

    Article  PubMed  CAS  Google Scholar 

  212. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor {alpha} produces insulin resistance in skeletal muscle by activation of inhibitor {kappa}B kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279:17070–17078.

    Article  PubMed  CAS  Google Scholar 

  213. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-[alpha] function. Nature. 1997;389:610–614.

    Article  PubMed  CAS  Google Scholar 

  214. Zamboni M, Di Francesco V, Garbin U, et al. Adiponectin gene expression and adipocyte NF-[kappa]B transcriptional activity in elderly overweight and obese women: inter-relationships with fat distribution, hs-CRP, leptin and insulin resistance. Int J Obes. 2007;31:1104–1109.

    Article  CAS  Google Scholar 

  215. Wu JT, Kral JG. The NF-[kappa]B/I[kappa]B signaling system: a molecular target in breast cancer therapy. J Surg Res. 2005;123:158–169.

    Article  PubMed  CAS  Google Scholar 

  216. Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): A potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA. 2001;98:10386–10391.

    Article  PubMed  CAS  Google Scholar 

  217. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–2135.

    Article  PubMed  CAS  Google Scholar 

  218. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–590.

    Article  PubMed  CAS  Google Scholar 

  219. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109:933–941.

    Article  PubMed  CAS  Google Scholar 

  220. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531–1543.

    PubMed  CAS  Google Scholar 

  221. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007;8:395–408.

    Article  PubMed  CAS  Google Scholar 

  222. Key TJ, Appleby PN, Reeves GK, et al. Endogenous Hormones Breast Cancer Collaborative G. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–1226.

    Article  PubMed  CAS  Google Scholar 

  223. Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61:126–130.

    PubMed  CAS  Google Scholar 

  224. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–1126.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes & Bone Disease, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

    Emily Jane Gallagher M.D., Ruslan Novosyadlyy M.D., Ph.D., Shoshana Yakar M.D. & Derek LeRoith

Authors
  1. Emily Jane Gallagher M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruslan Novosyadlyy M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shoshana Yakar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Derek LeRoith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Derek LeRoith .

Editor information

Editors and Affiliations

  1. Div. Endocrinology & Metabolism, Beth Israel Medical Center, East 17th Street 317, New York, 10003, U.S.A.

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gallagher, E.J., Novosyadlyy, R., Yakar, S., LeRoith, D. (2010). The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09841-8_36

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09841-8_36

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09840-1

  • Online ISBN: 978-0-387-09841-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation